Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.

As US medical device regulations moderate and EU regulations start to become more stringent, companies have a harder decision to make about which of the two markets they should target for initial launch of their products, says Thierry Chignon, senior partner at Mérieux Développement.

This Month's Profile Group: Biotechs Share Endocrine Enthusiasm, features profiles of Atterocor, Crinetics Pharmaceuticals, and OctreoPharm Sciences. Plus these Start-Ups Across Health Care: Biom’Up SA, KemPharm, LIM Innovations, Reflectance Medical, and Trino Therapeutics.